As GLP-1 RA use soars, experts are worried that patients may not be getting the right nutrients in their diets. How can ...

Maridebart cafraglutide, a novel injectable GLP-1 receptor agonist/GIP receptor antagonist, reduced body weight by up to ...

For overweight or obese individuals without diabetes, but with pre-existing cardiovascular disease, semaglutide (Ozempic, Wegovy) is not cost-effective at current pricing, new research shows.

As usage of the medications increases, Circana research indicates deli and produce could be bright spots for spending.

The evolution of AI, more limited-time product offerings and GLP-1 use for weight loss are among the issues expected to play ...

Holiday weight gain hits home for many come January. These days, folks making resolutions to slim down and get fit have an ...

Roche's strategic acquisition of Poseida Pharmaceuticals positions them as a leader in the allogeneic cell therapy market.

For overweight or obese individuals without diabetes, but with pre-existing cardiovascular disease, semaglutide (Ozempic, Wegovy) is not ...

This is the beginning of a revolution, and how you engage and how you attack it is going to really set the stage for your ...

Hello, Health Rounds Readers! Today we feature a study that found yet another potential health benefit of GLP-1 drugs, this ...

To identify this year’s Drugs to Watch 2025 list, Clarivate drew from expertise from over 160 Clarivate analysts covering ...